Navigation Links
Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
Date:3/26/2008

SOUTH SAN FRANCISCO, Calif., March 26 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced an agreement with W. C. Heraeus GmbH for the commercial manufacture and supply of picoplatin active pharmaceutical ingredient (API). Poniard is investigating picoplatin, the Company's lead product candidate, in four clinical trials, including the ongoing pivotal Phase 3 trial in small cell lung cancer, and is developing picoplatin as a potential new platform product for the treatment of solid tumors.

"This agreement is a major step forward in the development of picoplatin as a commercial oncology product and to ensure that picoplatin is available to patients and oncologists once FDA approval is obtained," said Ronald Martell, president and chief operating officer of Poniard Pharmaceuticals. "Heraeus is a high-quality partner which will provide Poniard with access to large-scale production, and has the capacity to meet our production and quality goals. They are a leader in the manufacture of pharmaceuticals, precious metals and synthesis chemistry."

Under the agreement, Heraeus will manufacture picoplatin API to meet cGMP requirements, and be ready to ship commercial quantities of picoplatin by 2009. Heraeus is the current manufacturer of picoplatin API for the Company's four ongoing clinical trials.

About Picoplatin

Picoplatin is a chemotherapeutic agent with an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 750 patients and has anti-tumor activity in multiple indications, with
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
2. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
3. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
4. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
5. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
6. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
8. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...wswire-USNewswire/ -- Abnormalities in auditory an... with autism spectrum disorder by using magnetoenc... today at the annual meeting of the Radiological S...MEG, we can record the tiny magnetic fields associ... Roberts, Ph.D., vice chair of research in the Dep...
(Date:11/27/2008)...ajority of acute lymphoblastic leukemia relapse ca...of diagnosis , , MEMPHIS, Tenn., Nov. 27 /P...ildren,s Research Hospital have identified distinc...en with acute lymphoblastic leukemia (ALL) that ca...ning treatments for ALL relapse in children and, u...
(Date:11/26/2008)... Subjects , , FRANKLIN, Mass., Nov. 26 /PRN...in Board: PLCSF) announced today that it has recei...nistration (FDA) for its U.S. pivotal trial to stu...ystem(TM) and associated therapy in the preventio... The FDA also approved PLC,s request to expand th...
(Date:11/25/2008)...espondents against expanding statin use broadly in...LS, N.J., Nov. 25 JUPITER, a clini...rdiovascular risk of healthy patients with elevate...lder adults, according to a national poll directed...took part in the online poll conducted by medical ...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 1Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 2Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 3Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen Activated ERK Kinase 28MEK 29 Inhibitors 1807 4Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 1Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 2Breast Cancer Unchanged in Black Women Despite Drop in HRT Use 16891 3Nanodrop test tubes created with a flip of a switch 2902 1Nanodrop test tubes created with a flip of a switch 2902 2Covenant House Welcomes His Holiness Pope Benedict XVI 16888 1
...ts Success with Positive Phase IIa Clinical,Trial ...New Application of Key,Product in AM-Pharma,s Pipe...arma B.V., the,biopharmaceutical company developin...mmatory diseases, today announced the positive,cli...e (AP) trial,for patients with ulcerative colitis,...
...etts, July 08, 2007 /PRNewswire/ -- , - ENDORSE Gl...ment Hospital-Wide Strategies to Optimize VTE Mana... and Provide Appropriate,prophylaxis to Prevent VT...g hospital,patients and most of these at-risk pati...ccording to data from the international,ENDORSE (E...
Other Medicine Technology:AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 2International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 3International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 4
(Date:12/1/2008)...se, personality illnesses common, study shows , ...hiatric disorders are common among young adults in...report shows. , To reach this finding, U.S. res...dents, aged 19 to 25, who took part in the Nationa...itions. , The study found that 45.8 percent of ...
(Date:12/1/2008)...s with the agency,s goals, commitment and resource...-- Responding to criticism that it has done a poor...S. Food and Drug Administration released a report ... , Among the most important changes in 2008 was...hips with state and local health departments to pr...
(Date:12/1/2008)... the National Cancer Institute,s cancer registry h...xperience delayed or incomplete radiation treatmen...is suboptimal care can lead to worse outcomes. , ...College and colleagues found that among a national...ncer registry patients aged 65 and older, almost 1...
(Date:12/1/2008)... Dec. 1 Due to the urgent need to ... of AIDS/HIV research and clinical care, publisher...mentary access to all archival online issues of th...ber in honor of World AIDS Day. Free online access... www.liebertpub.com/apc ) and AIDS Research and ...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
... States is due to birth defects, a study has found...lyzed the medical records of babies under 10 days ...t, such as, pulmonary valve stenosis, happen to be...italization. The study, enabled by the U.S. Cente...
...n reported worldwide due to vaccination programmes...due to measles by 50%. But a sixty percent success...goal. Western Pacific Region stands first with a ...ath followed by 75% in Asia. Dr Lara Wolfson of W...
...showed reasonable resistance to Tamiflu, an antivi...ird flu.// This caused anxiety in the medical comm...rus strain called as 294S was first found in Vietn...in in Egypt reveals that it has spread outside Asi...
...ted annually in Thailand is an ongoing challenge f... to Somchai Pinyopornpaitch, deputy director-gener...have increased for several years despite health of...land is currently 50 per 100,000 people, with 90,0...
Other Medicine News:
...isticated lathing techniques, intrinsically permea...hinsite lenses feature a center thickness of just ... powered Thinsite lenses maintain a 30% decrease i...ue design eliminates stress points to reduce the c...
Lifestyle Gp is a simultaneous vision lens with patented multi-aspheric back surface. Through a series of front and back surface curves, the LifeStyle Gp delivers up to +3.00 diopters of add. Plus, i
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach.
Medicine Products: